Document Detail

Utility of Cytokeratin 5/6, Cytokeratin 20, and p16 in the Diagnosis of Reactive Urothelial Atypia and Noninvasive Component of Urothelial Neoplasia.
MedLine Citation:
PMID:  22498670     Owner:  NLM     Status:  In-Data-Review    
BACKGROUND: : The utility of cytokeratin (CK)5/6 in distinguishing reactive urothelial atypia (RA) from urothelial carcinoma in situ (CIS) and from noninvasive component of high-grade papillary urothelial carcinoma (PUC) is unknown.
DESIGN: : Twenty RA with or without papillary hyperplasia and 90 noninvasive components of neoplastic urothelial lesions were submitted for immunostaining with CK5/6, CK20, and p16.
RESULTS: : Diffuse and strong reactivity involving the full or nearly full thickness of urothelium was observed with CK5/6 in 90% of RA cases. CK20 and p16 were negative in 90% and 85% of the RA cases, respectively. For CIS and noninvasive components of high-grade PUC without squamous differentiation, there was no CK5/6 staining or reactivity in the basal layer only. CK20 and p16 showed strong positivity in full thickness of urothelium in 75% to 85% of cases. CIS with weak/focal or negative reactivity for p16 or CK20 exhibited moderate cytologic atypia. Low-grade PUC displayed variable reactivity for CK5/6, CK20, and p16. Urothelial lesions with squamoid or basaloid features showed positive reactivity for CK5/6. Urothelial lesions with glandular differentiation showed negative reactivity for CK5/6.
CONCLUSIONS: : Diffuse CK5/6 reactivity in RA and negative CK5/6 reactivity in CIS and PUC may be helpful in distinguishing between these 2 entities.
Allison Edgecombe; Bich N Nguyen; Bojana Djordjevic; Eric C Belanger; Kien T Mai
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry     Volume:  20     ISSN:  1533-4058     ISO Abbreviation:  Appl. Immunohistochem. Mol. Morphol.     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-04-13     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100888796     Medline TA:  Appl Immunohistochem Mol Morphol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  264-71     Citation Subset:  IM    
Department of Pathology and Laboratory Medicine, The Ottawa Hospital and University of Ottawa, Ottawa, Ontario, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A 6-antibody panel for the classification of lung adenocarcinoma versus squamous cell carcinoma.
Next Document:  Is PAX2 a Reliable Marker in Differentiating Diffuse Malignant Mesotheliomas of Peritoneum From Sero...